Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2004

View Archived Issues

New data on AVP-893, a prototype of a novel class of antitumor agents from Avanir

Microtubule stabilizing agent potentiates anticancer activity in vitro

Significant prostate function improvements induced by an isoflavone red clover extract

Effective prevention of CINV with palonosetron before cisplatin-based chemotherapy

Therapeutic benefits of rosiglitazone in women with polycystic ovary syndrome

Improved safety profile of pegylated liposomal doxorubicin in metastatic breast cancer

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: BioVex

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Concurrent

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Cytopia

PAI-1 inhibitors designed and synthesized at Wyeth

Pyridine acetic acids developed as potent, orally active and selective aldose reductase inhibitors

Janssen claims new alphav integrin inhibitors and their use in cancer, osteoporosis, etc.

Three series of telomerase inhibitors described by researchers at Mitsui Chemicals

De Novo presents two series of beta-secretase inhibitors and their use in AD therapy

Novel proline-based antibacterial agents in early development at Dainippon

Dual PPARalpha/PPARgamma agonists designed at Roche

AstraZeneca patent covers dual NK1 antagonists/5-HT reuptake inhibitors and their use

PEDESTAL trial evaluates alagebrium for diastolic dysfunction

IR-103 shows HIV-1 specific immunogenicity in mouse model

Alovudine enters dose-finding phase IIa study in multiresistant HIV

Roche and Isotechnika restructure ISA-247 collaboration agreement

Apidra receives FDA approval

Private placement financing ensures progress of AEOL-10150 into clinic

Orphan medicinal product status for CA4P for anaplastic thyroid cancer

CT-2106 enters phase I/II trial for colorectal cancer

New preclinical data reported for MPC-4505

Phase II trial of MPC-7869 progresses on schedule

Bristol-Myers Squibb receives North American and Asian license for Javlor

Phase III program commences for Xerecept in peritumoral cerebral edema

Genasense available through Expanded Access Program for advanced melanoma

Phase II trial under way for R-112 in allergic rhinitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...